Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | TPMT | P51580 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4960464 | 0.81 | SIRT2 (0.42) | MCL1SIRT2MAOAMAOB | |
| SCHEMBL4962715 | 0.80 | POLB (0.42) | POLBCASP6PTGS2 | |
| SCHEMBL31557386 | 0.78 | MAOB (0.41) | POLBSIRT2MAOB | |
| SCHEMBL4960223 | 0.75 | SIRT2 (0.38) | MCL1SIRT2PTGS2ERN1 | |
| SCHEMBL4960819 | 0.73 | POLB (0.39) | POLBCASP6PTGS2PTGS1 | |
| SCHEMBL4964579 | 0.68 | MCL1 (0.38) | MCL1SIRT2ERN1MAOAMAOB | |
| SCHEMBL23910855 | 0.68 | SMN1; SMN2 (0.40) | MCL1SIRT2 | |
| SCHEMBL23910858 | 0.68 | SMN1; SMN2 (0.40) | MCL1SIRT2 | |
| SCHEMBL10399916 | 0.67 | POLB (0.39) | POLBCASP6ERN1 | |
| SCHEMBL23910714 | 0.66 | NFKB1 (0.39) | MCL1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871759-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006116158-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | POLB 3658/4885CASP6 4849/4885MCL1 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.